Karyopharm Therapeutics, Inc. Forecast, price target & analysts
Karyopharm Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Karyopharm Therapeutics, Inc. Classifications & Recommendation:
Karyopharm Therapeutics, Inc. Price Target
| Target Price | $15.30 |
| Price | $7.47 |
| Potential |
104.82%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Karyopharm Therapeutics, Inc. 2026 .
The average Karyopharm Therapeutics, Inc. target price is $15.30.
This is
104.82%
register free of charge
$22.05
195.18%
register free of charge
$6.06
18.88%
register free of charge
|
|
| A rating was issued by 12 analysts: 10 Analysts recommend Karyopharm Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Karyopharm Therapeutics, Inc. stock has an average upside potential 2026 of
104.82%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 145.24 | 150.79 |
| 0.54% | 3.82% | |
| EBITDA Margin | -82.00% | -87.94% |
| 7.18% | 7.24% | |
| Net Margin | -52.62% | -72.52% |
| 46.31% | 37.83% |
8 Analysts have issued a sales forecast Karyopharm Therapeutics, Inc. 2025 . The average Karyopharm Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Karyopharm Therapeutics, Inc. EBITDA forecast 2025. The average Karyopharm Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $-119m | 7.68% |
|---|---|---|
| 2025 |
$-133m
11.34%
Unlock
|
|
EBITDA Margin
| 2024 | -82.00% | 7.18% |
|---|---|---|
| 2025 |
-87.94%
7.24%
Unlock
|
|
8 Karyopharm Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Karyopharm Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -9.41 | -12.57 |
| 49.92% | 33.58% | |
| P/E | negative | |
| EV/Sales | 2.28 |
8 Analysts have issued a Karyopharm Therapeutics, Inc. forecast for earnings per share. The average Karyopharm Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Karyopharm Therapeutics, Inc....
Current Karyopharm Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Locked
➜
Locked
|
Locked | Nov 04 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 13 2025 |
| Baird |
Locked
➜
Locked
|
Locked | Oct 09 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Oct 09 2025 |
| Baird |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 16 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | May 13 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
RBC Capital:
Locked
➜
Locked
|
Nov 04 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 13 2025 |
|
Locked
Baird:
Locked
➜
Locked
|
Oct 09 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Oct 09 2025 |
|
Locked
Baird:
Locked
➜
Locked
|
Aug 12 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 16 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
May 13 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
